English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 22 July 2021, 19:26 HKT/SGT
Share:
    

Source: Sino Biopharmaceutical Limited
Sino Biopharmaceutical Donates Cash and Supplies Valued at RMB10 Million to Support Henan for Flood Relief and Preventing Epidemic

HONG KONG, July 22, 2021 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced the donation of cash and supplies valued at RMB10 million to support Henan for flood relief and preventing epidemic.

Henan province has been afflicted by the torrential rain storm and the severe flooding has drawn widespread concern. When a place is in trouble, help from all sides come to the rescue. With this thought in mind, Sino Biopharmaceutical, in fulfilling its social responsibility and living up to its role as a pharmaceutical company dedicated to healthcare, has donated both cash and emergency relief supplies each valued at RMB5 million via the Liaison Office of the Central People's Government in the Hong Kong S.A.R. These funds and supplies are to be used in supporting Henan province's efforts to provide emergency medical and rescue and relief services and prevent the emergence of an outbreak of disease or an epidemic in the wake of the devastation so as to protect the lives, safety and health of the public in Henan.

Ms. Cheng Cheung Ling, Vice Chairwoman and Executive Director of Sino Biopharmaceutical, said, "Capitalising on its professional strengths in the biopharmaceutical industry, the Group will closely monitor health issues and epidemic prevention preparations subsequent to this natural disaster, and donate supplies and medicines. Sino Biopharmaceutical regards safeguarding public health as its mission and responsibility. Let's stay together through thick and thin. Keep fighting and don't give up, Henan!"

About Sino Biopharmaceutical Limited (HKEX:1177)
Sino Biopharmaceutical Limited is a leading, innovative R&D driven pharmaceutical conglomerate in the PRC. Its business encompasses a fully-integrated chain which covers an array of R&D platforms, a line-up of intelligent production and a strong sales system. The Group's products have gained a competitive foothold in various therapeutic categories with promising potentials, comprising a variety of biopharmaceutical and chemical medicines for tumors, liver diseases, cardio-cerebral diseases, orthopedic diseases, respiratory system diseases and parenteral nutrition.

Sino Biopharm is a constituent stock of the following indices: MSCI Global Standard Indices - MSCI China Index, Hang Seng Index, Hang Seng China Enterprises Index, Hang Seng Composite Index, Hang Seng Healthcare Index, Hang Seng SCHK Mainland China Healthcare Index, Hang Seng Composite LargeCap Index, Hang Seng Composite LargeCap & MidCap Index, Hang Seng China (Hong Kong-listed) 100 Index and Hang Seng Stock Connect Hong Kong Index, etc.. Sino Biopharm was ranked as one of "Asia's Fab 50 Companies" by Forbes Asia for three consecutive years in 2016, 2017 and 2018.

For more information:
Strategic Financial Relations Limited
Vicky Lee +852 2864 4834 vicky.lee@sprg.com.hk
Fanny Yuen +852 2864 4853 fanny.yuen@sprg.com.hk
Mandy Wong +852 2114 4900 mandy.wong@sprg.com.hk
Website: www.sprg.com.hk


Topic: Press release summary
Source: Sino Biopharmaceutical Limited

Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Sino Biopharmaceutical Limited Releated News
July 22, 2021 19:25 HKT/SGT
中国生物制药捐资捐物人民币1,000万元驰援河南抗灾防疫
July 22, 2021 19:24 HKT/SGT
中國生物製藥捐資捐物人民幣1,000萬元馳援河南抗災防疫
May 24, 2021 17:14 HKT/SGT
中国生物制药2021年首季归属于母公司持有者应占盈利飙升118.5%至人民币19.14亿元
May 24, 2021 17:13 HKT/SGT
中國生物製藥2021年首季歸屬於母公司持有者應佔盈利飆升118.5%至人民幣19.14億元
May 24, 2021 17:12 HKT/SGT
Sino Biopharmaceutical 2021 First Quarterly Profit attributable to Owners of the Parent Soars 118.5% to RMB1.91 Billion
More news >>
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575